Company: VRCA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001660334-25-000006
Chunk: 21

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
 is disaggregated into separate lines of businesses and the Company does not differentiate the activities of its headquarters from the overall performance of the Company. The CEO makes resource allocation and business process decisions regarding the overall level of resources available and how to best deploy these resources.The single segment’s principal measure of segment profit and loss is consolidated net loss. The CEO considers actual and forecasted consolidated revenues, significant expenses, and consolidated net loss when evaluating performance. Significant expenses are amounts regularly provided to the CEO and included in consolidated net loss and include selling, general and administrative expenses and research and development expenses.The table below summarizes the significant revenue and expense categories regularly reviewed by the CEO for the three and nine months ended September 30, 2025 and 2024:For the Three Months Ended September 30,For the Nine Months Ended September 30,2025202420252024Revenue:Product revenue, net$3,607 $(1,865)$11,563 $6,259 License and collaboration revenue10,737 84 18,922 963 Total revenue14,344 (1,781)30,485 7,222 Less:Selling, general and administrative:Commercial (including payroll)4,976 10,169 13,604 28,561 General and administrative (including payroll)3,996 4,411 11,695 15,543 Stock-based compensation431 1,503 1,804 4,840 Total selling, general and administrative9,403 16,083 27,103 48,944 Research and development:YCANTH (VP-102)304 417 1,015 1,635 VP-315197 310 391 3,162 Common warts16 211 (50)371 Stock-based compensation287 605 828 1,568 Other unallocated expenses1,401 862 4,151 3,936 Research and development2,205 2,405 6,335 10,672 Cost of revenue1,109 435 2,040 2,115 Other segment items (a)1,901 2,156 4,819 5,868 Net loss$(274)$(22,860)$(9,812)$(60,377)

9

(a)Other segment items include interest income, interest expense, change in fair value of embedded derivative liability and other expenses.Cash and Cash Equ